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Abstract We determined frequency/types of K-ras
mutations in colorectal/lung cancer. ADx-K-ras kit (real-
time/double-loop probe PCR) was used to detect somatic
tumor gene mutations compared with Sanger DNA
sequencing using 583 colorectal and 244 lung cancer par-
affin-embedded clinical samples. Genomic DNA was used
in both methods; mutation rates at codons 12/13 and fre-
quency of each mutation were detected and compared. The
data show that 91.4% colorectal and 59.0% lung carcinoma
samples were detected conclusively by DNA sequencing,
whereas 100% colorectal and lung samples were detected
by ADx-K-ras kit. K-ras gene mutations were detected in
32.9–27.4% colorectal samples using kit and sequencing
methods, respectively. Whereas 10.6–8.3% lung cancer
samples were positively detected by kit and sequencing
methods, respectively. Notably, 172/677 showed mutations
and 467/677 showed wild type by both methods; 38 sam-
ples showed mutations with kit but wild type with
sequencing. Mutations in colorectal samples were as fol-
lows: GGT ? GAT/codon-12 (35.1%); GGC ? GAC/codon-13
(26.6%); GGT ? GTT/codon-12 (18.2%); and GGT ? GCT/
codon-12 (1.6%). Mutations in lung samples were as fol-
lows: GGT [ GTT/codon-12 (40.9%) and GGT [ GCT/
codon-12 (4.5%). In conclusion, K-ras mutations involved
32.2% colorectal and 10.6% lung samples among this
cohort. ADx-K-ras real-time PCR showed higher detection
rates (P \ 0.05). The kit method has good clinical appli-
cability as it is simple, fast, less prone to contamination and
hence can be used effectively and reliably for clinical
screening of somatic tumor gene mutations.
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Introduction
Targeted antineoplastic drugs have the selective inhibitory
function against a specific malignant molecule in tumor
cell and thus destroy the cell. Targeted drugs have minor
effect on normal tissue, and thus, the targeted drugs cause
least toxic and side effects in patients with significant
improvement in their quality of life. At present, targeted
drug is the optimal drug and represents the future trend of
drug development in tumor therapy [1, 2]. The increasing
body of evidence suggests that the therapeutic effect of
targeted drug is correlated with the gene status of targeted
molecular signal pathway, e.g., Erbitux and Panitumumab
in regard with K-ras mutation [3–5]; Iressa and Tarceva
regarding EGFR mutation [2, 6–10]; Herceptin and Her-2
in regard with overexpression [11].
K-ras gene plays an important role in regulating
cell growth and differentiation [12]. Certain tumors, such
as colorectal carcinoma, lung carcinoma, pancreatic
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carcinoma, etc., relate with K-ras gene mutation. The
mutation rate of K-ras gene was reported to be 20–40% in
colorectal carcinoma, 10–17% in lung carcinoma and 59%
in pancreatic carcinoma [3, 13]. It was also reported [4] that
about 95% K-ras mutations were related with the mutations
of codons 12–13. Of note, the US food and drug adminis-
tration (FDA) advised in 2009 that K-ras gene mutations
required to be examined before metastatic colorectal carci-
noma was treated by targeted drugs such as Erbitux and
Panitumumab. Therefore, it is important that K-ras gene
mutations in clinical tumor samples be identified promptly
and accurately.
In this study, we tested K-ras gene in colorectal carci-
noma and lung carcinoma patients using ADx-K-ras real-
time PCR kit and Sanger DNA sequencing methods,
explored the frequency and types of K-ras gene mutations
and compared the clinical applicability between ADx-K-
ras real-time PCR kit and Sanger DNA sequencing meth-
ods for identifying K-ras gene mutations.
Materials and Methods
Samples
A total of 827 clinical samples were collected as follows:
200 colorectal and 208 lung carcinoma samples were col-
lected from No.1 affiliated Hospital of Xiamen University;
315 colorectal carcinoma samples were collected from
Fujian Province Cancer Hospital; 68 colorectal and 36 lung
carcinoma samples were collected from PLA-174 Hospital.
The study samples comprised of 8 paraffin sections (5 lm
thick each) per sample that were confirmed to contain
tumor tissue by pathologic diagnosis, and the preservation
time was less than 2 years.
DNA Extraction
Five paraffin sections/sample were used to extract DNA; other
3 sections were maintained at room temperature for backup.
DNA was extracted using QIAamp DNA formalin-fixed
paraffin-embedded (FFPE) Tissue Kit (Qiagen, Germany)
following the manufacturer’s instructions. Extracted DNA
was dissolved in Tris–HCl (10 mmol/l, pH 8.0) to check the
quality and measure DNA concentration by ultraviolet spec-
trophotometry. DNA concentration was adjusted to 10 ng/ll
and 2 ng/ll with Tris–HCl solution (10 mmol/l, pH 8.0), and
samples were stored at -20C until use.
Sanger DNA Sequencing
K-ras codons 12–13 were amplified using the following
primers (Shanghai Shenggong Bioengineer Co. Ltd.,
China): K-ce-1-F: 50-CTG GTG GAG TAT TTG ATA
GTG-30; K-ce-1-R: 50-CCC AAG GAA AGT AAA GTTC-
30. PCR reaction mix (50 ll) comprised the following:
5.0 ll of 109 buffer [166 mM (NH4)2SO4, 670 mM Tris–
HCl pH 8.0, 67 lM EDTA and 0.85 mg/ml BSA], 3.0 ll of
25 mM MgCl2, 200 lM of each dNTP,each primer 0.2 lM
of each primer, 2U of Taq-HS DNA polymerase (TakaRa,
China) and 5 ll of 10 ng/ll genomic DNA. Reaction
conditions were as follows: pre-denaturation at 96C for
2 min, denaturation at 96C for 15 s, 66–56C (tempera-
ture was decreased by 1C after each cycle) for 25 s, 72C
for 20 s, 10 cycles of: 94C for 15 s, 56C for 25 s, 72C
for 20 s; a total of 35 cycles. At least one normal human
DNA sample was included as positive control in each PCR,
and sterile water was included as negative control to rule
out any possibility for external contamination. The PCR
product was sequenced by the above-referred manufac-
turer. Each batch of sample contained known wild-type
sample for quality control, and the following primer was
sued for sequencing: K-ce-1-F: 50-CTG GTG GAG TAT
TTG ATA GTG-30.
ADx-K-ras Fluorescence PCR Kit
ADx-K-ras PCR detection kit was purchased from Amoy
Diagnostics Ltd., Fujian, China. For fluorescence PCR
determination (StrataGene MX3000P) of 7 types of K-ras
gene mutations, the detection sites are listed in Table 1.
Using the protocol as recommended by the manufacturer,
10 samples were processed each time with one positive
control for quality control and one no template control
(NTC). If the amplification curve was not classic S-curve
or if Ct value was [30, the result was determined as wild
type (mutation negative).
Statistical Analysis
The data were analyzed using SPSS13.0 software and
compared using paired chi-square (v2) test. All P val-
ues \ 0.05 were considered statistically significant.
Results
A total of 827 samples were tested that included 583
samples of colorectal carcinoma and 244 samples of lung
carcinoma. Of the 583 colorectal carcinoma samples tested
using ADx-K-ras real-time PCR kit, 192 samples detected
positive for K-ras gene mutation, while 391 samples were
detected as wild type (mutation negative), and thus, the
mutation rate was 32.2%. When these samples were tested
using Sanger sequencing, 160 samples detected positive for
K-ras gene mutation, and therefore, the mutation rate was
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30.0%. Of the 244 lung carcinoma samples tested using
ADx-K-ras real-time PCR kit, 26 samples detected positive
for K-ras gene mutation, while 218 samples were detected
as wild type (mutation negative), and thus, the mutation
rate was 10.6%. When these samples were tested using
Sanger sequencing, 12 samples detected positive for K-ras
gene mutation, and therefore, the mutation rate was 8.3%.
The respective distribution of positive K-ras mutation types
in colorectal carcinoma and lung carcinoma samples is
summarized in Table 2. Whereas 7 hot mutation sites are
shown in Fig. 1, and the mutation frequencies of 7 hot
K-ras gene mutation sites are shown in Fig. 2.
Among the total 827 samples, each samples tested by
ADx-K-ras real-time PCR kit yielded accurate and distinct
result, and the success rate was 100%. However, certain
samples failed detection using Sanger DNA sequencing, or
the result could not be confirmed because of the sequencing
map errors, and consequently, 533 out of 583 colorectal
carcinoma samples met with definitive sequencing results.
Similarly, only 144 out of 244 lung carcinoma samples had
sequencing results. Thus, 50 colorectal carcinoma samples
and 100 lung carcinoma samples did not yield the
sequencing results. The success rate using Sanger DNA
sequencing was 81.9%, and in 18.1% cases, the method
failed to detect the K-ras mutation. The K-ras mutation
results of samples with integrate data are summarized in
Table 3. The data show that GGT [ GAT at site 2 of
codon 12 was the most common mutation in colorectal
carcinoma samples, and the prevalence rate of this muta-
tion among total mutations was 35.1% (66/188) which was
followed, in order, by GGC [ GAA at site 2 of codon 13,
GGC [ GAC with prevalence rate of 26.6% (50/188) and
GGT [ GTT at site 2 of codon 12 with prevalence rate of
18.2% (35/188). The GGT [ GCT mutation at site 1 of
codon 12 was the most uncommon mutation with the
prevalence rate of 1.6% (3/188). Among the lung carci-
noma samples, the GGT [ GTT mutation at site 1 of codon
12 was the most common mutation with the prevalence rate
of 40.9% (9/22), whereas the GGT [ GCT mutation at site
1 of codon 12 was the most uncommon mutation with the
prevalence rate of 4.5% (1/22); see Table 2.
Of the 827 samples, 677 samples were tested with both
Sanger sequencing and ADx-K-ras real-time PCR methods.
The mutation and wild-type phenotype rates were
Table 1 The 7 hot mutation
sites on codons 12 and 13 of
human K-ras gene
Mutation name Amino acid
residue change
Base change Cosmic ID ADx-K-ras
commercial name
Gly12Ser Glycin to serine GGT [ AGT 517 12-1-A
Gly12Arg Glycin to serine GGT [ CGT 518 12-1-C
Gly12Cys Glycin to serine GGT [ TGT 516 12-1-T
Gly12Asp Glycin to aspartic acid GGT [ GAT 521 12-2-A
Gly12Ala Glycin to propylene GGT [ GCT 522 12-2-C
Gly12Val Glycin to valine GGT [ GTT 520 12-2-T
Gly13Asp Glycin to aspartic acid GGC [ GAC 532 13-2-A
Table 2 K-ras gene mutations
detected in 827 samples





Total samples 583 583 244 244
Detected samples 583 533 244 144
Mutation rate (%) 32.2 30.0 10.6 8.3
Mutants 192 160 26 12
12-1-A 12 5 5 0
12-1-C 3 1 1 0
12-1-T 28 11 10 6
12-2-A 66 57 5 1
12-2-C 15 12 2 1
12-2-T 35 30 2 1
13-2-A 51 45 5 4
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statistically analyzed, and the conformity of two methods
was calculated (Table 4). In this regard, 172 out of 677
samples tested positive by Sanger sequencing, and the
positivity for K-ras gene mutation was verified by both
methods, whereas 467 samples were verified as wild type
by both methods. However, 38 samples detected as
mutants by ADx-K-ras real-time PCR kit were detected as
wild type by Sanger sequencing. The conformity of two
methods for mutation was 100.0%, for wild type was
92.5% and overall conformity was 94.4% (v2 = 36.03;
P \ 0.005). Obviously, the mutation rate detected by
ADx-K-ras real-time PCR kit was higher than that of
Sanger sequencing.
Discussion
In the present study, we compared rates of K-ras gene
mutation detection using colorectal carcinoma and lung
carcinoma samples between ADx-K-ras real-time PCR kit
and traditional Sanger DNA sequencing methods. Our data
show that the K-ras gene mutation rate of colorectal
Fig. 1 Graphic representation
of 7 hot K-ras gene mutation
sites
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carcinoma was 32.2% which is similar to that (20–40%)
reported by the previous studies reports [3, 4, 14–17]. Of
note, the mutation rate of colorectal carcinoma was higher
than that (9.0%) of lung carcinoma. Moreover,
GGT [ GAT mutation at site 2 of codon 12 was the most
common mutation (35.1%; 66/188) found in colorectal
carcinoma samples. Next, the occurrence of GGC [ GAC
mutation at site 2 of codon 13 was 26.6% (50/188),
GGT [ GTT at site 2 of codon 12 was 18.2% (35/188), and
GGT [ CGT at site 1 of codon 12 was merely 1.6% (3/
188). In lung carcinoma samples, GGT [ TGT mutation at
site 1 of codon 12 was the most common mutation (40.9%;
9/22), and the GGT [ CGT mutation at site 1 of codon 12
was the rarest mutation found (4.5%; 1/22). The COSIC
database search revealed that the most common K-ras
mutation was GGT [ GAT that occurred at site 2 of
codon 12 with the prevalence rate of 36.9%, whereas the
rarest mutation was GGT [ CGT that occurred at site 1
of codon 12 with the prevalence rate of 4.4%. These data
show that the results of this study regarding types of
K-ras gene mutations are congruent with the previous
reports [2, 18].
However, regarding concerns with the use of formalin-
fixed, paraffin-embedded tissue samples in this study,
certain samples of extracted DNA showed fragmentation
(less than 300 bp) due perhaps to cross-linking between
formalin and DNA as reported previously [19–22]. Since
the partial DNA cross-linking was not restored, therefore,
extracted DNA quality was poor than that of fresh tissue.
Notably, all the 827 samples tested by ADx-K-ras real-time
PCR kit produced accurate and distinct results, and thus,
the success rate for detection was 100%. On the other hand,
the success rate of detection using Sanger sequencing
method was 81.9% (677/827). It indicates that ADx-K-ras
real-time PCR kit method was more proficient than tradi-
tional Sanger DNA sequencing in detecting K-ras gene
mutations although the extracted DNA quality was poor.
It might be due to the reason that the DNA fragment
amplified by ADx-K-ras real-time PCR kit was short (less
than 100 bp), and hence, the adverse effects of DNA
fragmentation were endured. Besides, the success rate of
mutation detection was 91.4% (533/583) for colorectal
carcinoma and 59.0% (144/244) for lung carcinoma which
may be due, at least in part, to excessive formalin perfusion
in loose pulmonary carcinoma tissue as compared with
more compact colorectal carcinoma tissue.
Comparing between ADx-K-ras real-time PCR kit and
Sanger DNA sequencing methods, the concordance rate of
mutation detection was 100.0%, whereas the concordance
rate of wild-type phenotype detection was 92.5% and the
overall concordance rate was 94.4%. Statistical analysis
(v2 = 36.03) showed that the difference was significant
(P \ 0.005) based on the level of a = 0.05. Thus, the rate
of K-ras gene mutation detection using ADx-K-ras real-
time PCR kit was significantly higher than that of Sanger
DNA sequencing. Importantly, the kit method involves
one-step short-time (100 min) reaction in a sealed tube
which is the least prone to external contamination. As
opposed to traditional Sanger DNA sequencing being a
more complicated, prone to contamination and time-
consuming procedure, the real-time PCR is a relatively
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Fig. 2 Mutation frequencies of 7 hot K-ras gene mutation sites
Table 3 K-ras gene mutations detected in 533 samples with inte-
grated data









Total samples 533 533 144 144
Mutation rate (%) 35.3 30.0 15.3 8.3
Mutants 188 160 22 12
12-1-A 11 5 4 0
12-1-C 3 1 1 0
12-1-T 26 11 9 6
12-2-A 66 57 4 1
12-2-C 15 12 2 1
12-2-T 35 30 2 1
13-2-A 50 45 4 4
Table 4 Comparison of two gene mutation detection methods
ADx-K-ras Sanger DNA sequencing Sum
Mutant Wild type
Mutant 172 38 210
Wild type 0 467 467
Sum 172 505 677
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In conclusion, ADx-K-ras real-time PCR has signifi-
cantly higher rates of K-ras gene mutation detection than
Sanger DNA sequencing. In addition, the former technique
is relatively simple, fast and less prone to external con-
tamination. With its good clinical applicability, ADx-K-ras
real-time PCR is an effective and reliable tool for clinical
screening of somatic gene mutations in tumors such as
colorectal and lung carcinoma.
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